triple-hormone-receptor agonist retatrutide for obesity Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio Retatrutide: FDA approval time, trial

These intensive research and development efforts are in response to the increasing prevalence of the disease and related co-morbidities, realization by care givers that successful glycemic control will likely require combination therapy, a growing understanding of the pathophysiology of the disease, and the identification and validation of new pharmacological targets

[DOI] [PMC free article] [PubMed] [Google Scholar] 192.Yi L., Maier A.B., Tao R., Lin Z., Vaidya A., Pendse S., Thasma S., Andhalkar N., Avhad G., Kumbhar V

"The demand for these drugs is soaring, and insurers are continuing to not cover these drugs, expecting and pushing patients to buy them online and pay in cash, but those compounding pharmacies are so dangerous

Retatrutide does not yet have dedicated cardiovascular or renal outcome trials, though Phase 3 studies evaluating these endpoints are currently enrolling participants with expected completion in 2026

Conclusion Proper Retatrutide injection technique is critical for your safety and treatment success

If retatrutide shows cardiovascular benefit similar to or better than semaglutide, it would significantly strengthen the case for approval and potentially expand the labeled indications